Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1541-1545

  Kotani, K ^a,b   Kimura, S ^c   Kinugasa, E ^c   Ogata, H ^c   Caccavello, R ^b   Taniguchi, N ^a   Gugliucci, A ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

^c SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Cardiovascular disease; Lipoprotein subfraction; Oxidation; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE;

EID: 80052220901     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900445     Document Type: Article

References (12)

1. Shoji T, Nishizawa Y, Kawagishi T, et al: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277-1284.
2. Shoji T, Ishimura E, Inaba M, et al: Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 2001; 38(4 suppl 1): S30-S33.
3. Bhagavan NV, Lai EM, Rios PA, et al: Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-585.
4. Sharma R, Gaze DC, Pellerin D, et al: Ischemiamodified albumin predicts mortality in ESRD. Am J Kidney Dis 2006; 47: 493-502.
5. Piwowar A, Knapik-Kordecka M, Warwas M: Ischemia-modified albumin level in type 2 diabetes mellitus-preliminary report. Dis Markers 2008; 24: 311-317.
6. Duarte MM, Rocha JB, Moresco RN, et al: Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009; 42: 666-671.
7. Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-1379.
8. Gugliucci A, Mehlhaff K, Kinugasa E, et al: Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007; 377: 213-220.
9. Stenvinkel P: Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant 2003; 18(suppl 8): viii17-viii22.
10. Lim CS, Vaziri ND: Iron and oxidative stress in renal insufficiency. Am J Nephrol 2004; 24: 569-575.
11. Sezer MT, Akin H, Demir M, et al: The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients. J Nephrol 2007; 20: 196-203.
12. Cichota LC, Moresco RN, Duarte MM, et al: Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008; 22: 1-5.